CRISPR Therapeutics AG — Director's Dealing 2020

Jun 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-06-11

Reporting Person: Greene John (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-11	Stock Option (Right to Buy)	$59.70	A	15000	Acquired	2030-06-11	Common Stock (15000)	Direct

Footnotes

F1: This option was granted on June 11, 2020 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2020; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2021 Annual General Meeting of Shareholders.